Nan Fung Trinity HK Ltd. Increases Stake in Bicara Therapeutics Inc. $BCAX

Nan Fung Trinity HK Ltd. boosted its holdings in Bicara Therapeutics Inc. (NASDAQ:BCAX) by 12.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 384,885 shares of the company’s stock after buying an additional 42,000 shares during the period. Nan Fung Trinity HK Ltd.’s holdings in Bicara Therapeutics were worth $6,077,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the company. AQR Capital Management LLC purchased a new position in Bicara Therapeutics in the first quarter worth $248,000. Woodline Partners LP lifted its holdings in Bicara Therapeutics by 26.5% in the 1st quarter. Woodline Partners LP now owns 348,690 shares of the company’s stock worth $4,543,000 after buying an additional 72,998 shares during the period. TD Asset Management Inc lifted its position in shares of Bicara Therapeutics by 71.5% in the 2nd quarter. TD Asset Management Inc now owns 224,538 shares of the company’s stock worth $2,086,000 after purchasing an additional 93,600 shares during the period. Geode Capital Management LLC lifted its stake in shares of Bicara Therapeutics by 36.8% in the 2nd quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock valued at $6,248,000 after purchasing an additional 180,833 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey lifted its position in Bicara Therapeutics by 119.6% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 8,109 shares of the company’s stock valued at $75,000 after acquiring an additional 4,417 shares during the period.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. UBS Group reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Mizuho raised shares of Bicara Therapeutics to a “hold” rating in a report on Thursday, December 18th. BTIG Research reiterated a “buy” rating on shares of Bicara Therapeutics in a research note on Thursday, January 15th. Wedbush reissued an “outperform” rating and set a $30.00 price target on shares of Bicara Therapeutics in a research report on Tuesday, January 13th. Finally, HC Wainwright restated a “buy” rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. Seven analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $28.33.

Insider Buying and Selling at Bicara Therapeutics

In other Bicara Therapeutics news, CEO Claire Mazumdar sold 41,163 shares of the business’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $18.86, for a total transaction of $776,334.18. Following the completion of the sale, the chief executive officer owned 309,892 shares of the company’s stock, valued at approximately $5,844,563.12. The trade was a 11.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Ivan Hyep sold 17,795 shares of the company’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $18.55, for a total value of $330,097.25. Following the completion of the sale, the chief financial officer owned 145,355 shares of the company’s stock, valued at approximately $2,696,335.25. The trade was a 10.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 95,922 shares of company stock valued at $1,784,142 over the last three months. Insiders own 15.50% of the company’s stock.

Bicara Therapeutics Stock Performance

Bicara Therapeutics stock opened at $16.80 on Friday. The stock has a market cap of $920.34 million, a PE ratio of -7.50 and a beta of -0.79. Bicara Therapeutics Inc. has a one year low of $7.80 and a one year high of $19.71. The stock has a fifty day moving average of $17.52 and a 200 day moving average of $14.89.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Monday, November 10th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.12). As a group, sell-side analysts predict that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.